Busulfan (BU)

DRUG16 trials

Sponsors

Nanfang Hospital, Southern Medical University, Masonic Cancer Center, University of Minnesota, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaAllogeneic Hematopoietic Stem Cell TransplantationAutologous Hematopoietic Stem Cell TransplantationBiphenotypic/Undifferentiated LeukemiaBurkitt LymphomaBusulfanChronic Myelogenous Leukemia

Phase 2

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

CompletedNCT02671708

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Autologous Hematopoietic Stem Cell Transplantation, Conditioning

Start: 2016-01-31End: 2020-02-28Updated: 2020-03-03

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

CompletedNCT02744742

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2016-04-18End: 2021-09-30Updated: 2022-02-14

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Diffuse Large B-cell Lymphoma

Start: 2017-07-05End: 2020-06-30Target: 122Updated: 2017-10-12

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma

Start: 2018-01-02End: 2021-12-31Target: 122Updated: 2020-02-25

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning +1

Start: 2018-06-15End: 2022-04-01Target: 60Updated: 2020-12-22

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditions, Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

Start: 2018-07-31End: 2022-06-30Target: 122Updated: 2018-07-24

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruitingNCT03674411

Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8

Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Primary Central Nervous System Lymphoma

Start: 2018-11-30End: 2021-10-31Target: 20Updated: 2018-11-07

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors

Start: 2019-09-30End: 2023-08-31Target: 196Updated: 2019-09-23

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors +1

Start: 2019-10-31End: 2023-09-30Target: 196Updated: 2019-10-10

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Secondary Acute Myeloid Leukemia Evolving From MDS

Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not yet recruitingNCT07052422

Nanfang Hospital, Southern Medical UniversityConditioning, Hematopoietic Stem Cell Transplantation (HSCT), Myeloid Malignancies +1

Start: 2025-07-15End: 2029-12-31Target: 160Updated: 2025-07-04

Phase 3

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

CompletedNCT02670252

Nanfang Hospital, Southern Medical UniversityAcute Lymphocytic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan +1

Start: 2016-01-31End: 2022-02-28Updated: 2022-04-08

Unknown Phase

TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission

Not yet recruitingNCT07563920

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAcute Myeloid Leukemia

Start: 2026-06-01End: 2030-06-01Target: 93Updated: 2026-05-04

Related Papers

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

2025-08-121 citations

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.

2023-01-2319 citations

Idarubicin plus <scp>BuCy</scp> versus <scp>BuCy</scp> conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing <scp>auto‐HSCT</scp>: An open‐label, multicenter, randomized phase 3 trial

American Journal of Hematology2023-01-015 citations

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood2022-11-15

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial

Journal of Clinical Oncology2022-09-0948 citations

Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)

Biology of Blood and Marrow Transplantation2020-01-23

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Blood2019-11-134 citations